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Abstract 
Tick-borne encephalitis (TBE) is caused by the neurotropic tick-borne encephalitis virus (TBEV). In dogs, this virus may 
affect the central nervous system (CNS), causing meningoencephalitis, meningomyelitis, radiculitis or any combina-
tion of these. Diagnosis of TBE relies on a combination of clinical signs of CNS disease and laboratory findings, includ-
ing CSF pleocytosis and serum TBEV antibody titers. Exposure to TBEV does not necessarily cause clinical disease, and 
seroprevalence has been reported as high as 40% in endemic areas. This causes concerns of over-diagnosing TBE 
in dogs with CNS disease. By examining TBEV antibodies in dogs with and without neurological disease in a TBEV 
endemic area, this study aimed to evaluate the diagnostic value of TBEV antibodies in the cerebrospinal fluid (CSF) in 
dogs. Eighty-nine dogs were included in the study, 56 with neurological disease and 33 neurologically normal control 
dogs. A positive TBEV CSF and serum IgG antibody titer (> 126 U/mL) was found in 3/89 dogs (3.4%). A positive serum 
TBEV antibody titer was found in 11 of the 89 dogs (12.4%). None of the control dogs showed a positive CSF antibody 
titer, whilst two showed positive serum concentrations. A positive CSF IgG antibody titer supports a clinical diagnosis 
of TBE in patients with acute onset of CNS disease and may help reduce the risk of over-diagnosis.
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Findings
Tick-borne encephalitis (TBE) is caused by the neuro-
tropic tick-borne encephalitis virus (TBEV) [1, 2]. In 
Europe, this virus is transmitted mainly by Ixodes ricinus 
ticks [3]. TBEV affects the central nervous system (CNS), 
most commonly the brain but may also involve the spi-
nal cord and nerve roots, causing meningoencephalitis, 
meningomyelitis or radiculitis [4]. Canine TBE has been 
characterized by clinical signs that are almost similar to 
TBE in humans, but with lower morbidity and a higher 
mortality rate compared to humans [3, 5–7]. Although 
the prognosis for canine TBE has been described as poor, 
affected dogs may recover without complications [8]. A 
diagnosis of TBE relies on a combination of clinical and 
laboratory findings [9]. In contrast to other viral infec-
tions, polymerase chain reaction (PCR) methods are 
rarely useful for the in  vivo diagnosis of TBE since by 
the time neurological symptoms become manifest, the 
virus has already been cleared from the blood and the 
cerebrospinal fluid (CSF). In humans, laboratory confir-
mation of TBE is based on CSF analysis and evaluation 
of TBEV specific antibody titers in serum and/or CSF 
[10, 11]. TBEV antibody testing of CSF is considered a 
reliable diagnostic tool, and TBEV specific antibodies 
are found in the majority of human patients [9, 12, 13]. 
In veterinary medicine, the clinical diagnosis is com-
monly based on IgG seropositivity and CSF pleocyto-
sis in dogs with signs of acute CNS disease localized to 
the brain [3]. However, as seroconversion is common in 
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in the Nordic countries [14–16], seropositivity becomes 
of questionable value [3, 17]. Analysis of TBEV antibody 
titers in CSF has therefore been suggested as an acute 
diagnostic test for dogs with presumed TBE [17, 18]. By 
examining TBEV antibodies in CSF in a group of dogs, 
with and without neurological signs in a TBEV endemic 
area, this study aimed to evaluate the diagnostic value of 
antibodies in CSF. We hypothesized that if present, TBEV 
antibody titers are positive in CSF from dogs presenting 
with an acute onset of signs localized to the brain.
Privately owned dogs were prospectively recruited 
between 2012 and 2017 at Anicura Albano Animal Hos-
pital, Stockholm, Sweden. Ethical approval from Animal 
Ethics Committee of Sweden was obtained, and dogs 
were only included if owners had given consent to par-
ticipate. Dogs with neurological disease were recruited 
from patients presenting to the neurology service, and 
dogs without neurological disease, were recruited from 
dogs presenting for euthanasia due to non-neurologi-
cal disease, through the emergency service at Anicura 
Albano Animal Hospital. All dogs underwent a clini-
cal examination and dogs with CNS disease also under-
went a neurological examination by a board-certified 
neurologist or a veterinarian in training to become a 
Swedish specialist in neurology in dogs and cats. Dogs 
with neurological disease were divided into two groups. 
Group A included dogs admitted with an acute onset 
of neurological signs localised to the brain and group B 
included dogs with signs of other neurological localiza-
tion or chronic (> 2 weeks) neurological signs localised to 
the brain. Group C included dogs euthanized for reasons 
unrelated to a neurological disorder and without neuro-
logical signs. For dogs with neurological disease (group 
A and B), CSF and blood sampling were performed as 
part of their routine clinical work-up. In group A (n  = 
20) and B (n  =  36) all dogs had CSF cell count and pro-
tein concentration analyzed. Polymerase chain reaction 
was used to analyze for infectious diseases (Canine dis-
temper virus, Neospora caninum, Toxoplasma gondii 
and Anaplasma phagocytophilium) for 10 dogs in Group 
A and 20 dogs in Group B. For dogs in group C, admit-
ted for euthanasia, blood sampling was performed as 
the venous catheter was inserted and the CSF was taken 
immediately post-mortem. The CSF was taken from the 
cerebellomedullary cistern in all dogs and samples were 
analyzed within 30 min of collection. Cerebrospinal fluid 
was interpreted to have pleocytosis if there were  >  5 
nucleated cells/µL, and pleocytosis was classified by the 
primary cell population if one cell type comprised  >  50%. 
Protein concentration was considered to be increased if 
>  0.25 g/L at the cerebello-medullary cistern [19]. Serum 
and CSF samples from all dogs were immediately fro-
zen and stored at − 18 °C. Samples were then packed on 
dry ice and shipped by express delivery to the veterinary 
diagnostic laboratory Laboklin (Bad Kissingen, Ger-
many) for analysis for IgG antibodies against TBEV (IgG 
TBEV). The method used was the commercially available 
enzyme-linked immunosorbent assay (ELISA) Immu-
nozyme FSME (TBE)  IgGa. An ELISA cut-off value of 126 
U/mL for both serum and CSF was used according to the 
manufacturer’s recommendation at the time the study 
was initiated.
Descriptive statistics were used for presenting data 
including signalment, TBEV antibody levels in serum 
and CSF, CSF pleocytosis and CSF protein concentration. 
Continuous variables are presented as median and inter-
quartile range (IQR).
A total of 89 dogs were included in the study. Informa-
tion on signalment and TBEV antibody titers in CSF and 
serum of included dogs is summarised in Table 1. A posi-
tive TBEV CSF antibody titer was found in three of the 89 
dogs (3.4%). These three dogs belonged to group A and 
the individual TBEV CSF antibody titer of these dogs was 
131.8, 194.3 and 188.0 U/mL respectively. The three dogs, 
a Rottweiler, a Labrador and a Bedlingtonterrier, lived in 
the Stockholm archipelago, a highly TBE endemic area, 
and all presented with fever, decreased mentation, hyper-
esthesia, ataxia, hypermetria, disorientation and seizures. 
Two (2/3) dogs presented with CSF pleocytosis, the third 
dog with an unremarkable CSF was on steroids before 
sampling. All three dogs also presented with a positive 
TBEV serum antibody titer (142.8, 415.8 and 169.5 U/mL 
respectively).
A positive serum TBEV antibody titer was found in 11 
of the 89 dogs (12.4%); 5 belonged to group A; 4 to group 
B; and 2 to group C. The two additional dogs from group 
A presented with central vestibular signs without fever, 
the dogs from group B presented with optic neuritis (n  = 
1), neoplasia (n  =  1), polyneuropathy (involving cranial 
nerves) (n  =  1) and steroid responsive meningitis-arte-
ritis (n  =  1). All PCR tests for other infectious diseases 
in CSF, including the CSF samples from the three dogs 
with a positive CSF TBEV antibody titer, were negative. 
The three TBEV CSF antibody positive dogs were all 
treated with immunosuppressant doses of corticosteroids 
between two and three weeks and all three dogs survived.
Due to the low number of CSF positive dogs in this 
study, the accurate diagnostic value of TBEV antibod-
ies in CSF could not be determined. However, a positive 
TBEV antibody titer in CSF was a rare finding and as 
hypothesized only included dogs presented with an acute 
onset of neurological sings localized to the brain. Of the 
eight dogs from group B and C (n  =  69) that presented 
with a positive serum TBEV antibody titer none showed 
a positive CSF TBEV antibody titer. In addition, two dogs 
without neurological signs presented with a positive 
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serum TBEV antibody titer. The diagnosis of TBE should 
be based on clinical and laboratory findings with CSF 
pleocytosis confirming CNS involvement and serological 
testing proving exposure to the TBEV. The Immunozyme 
FSM IgG ELISA has been shown to be a highly specific 
test for the detection of antibodies in serum against 
TBEV in dogs [20] however its sensitivity and specificity 
for TBEV antibodies in CSF has not been determined. To 
the authors’ knowledge, this is the first study measuring 
TBEV antibody titers in serum and CSF of both neuro-
logically affected and unaffected dogs in a TBE endemic 
area. We used the manufacturers recommended antibody 
cut-off value for TBEV positivity of 126  U/mL in CSF 
which is in agreement with a previous study of TBE in 
dogs [17]. The manufacturer has since changed the cut-
off value to  >  20  U/mL. With a cut-off value of TBEV 
antibodies of  >  20 U/mL in the CSF, the majority of dogs 
included in this study (57.3%), regardless of neurologi-
cal status, would have been considered TBEV positive. 
However, TBEV CSF antibody testing would then be of 
no clinical value, and erroneous clinical diagnoses might 
be made depending on the cut off value provided by the 
laboratory.
It was a limitation to our study that the CSF TBEV 
positive dogs were not confirmed by neutralization 
test. We cannot rule out the possibility that the anti-
bodies passively diffused from serum into CSF due to 
a blood–brain-barrier disruption. However, the study 
included dogs presenting with an acute meningoen-
cephalitis and even higher serum TBEV antibody titers 
with low CSF TBEV antibodies. Also, as all three dogs 
survived, histopathological examination including RT-
qPCR was not an option, and paired serum samples 
were not analysed as the dogs were not available for fol-
low up sampling.
Conclusions
The present study investigated CSF IgG antibody titers 
in dogs with and without neurological signs and found 
that only in dogs with acute neurological signs from 
the brain, TBEV antibody titers were positive in both 
serum and CSF. If only performing serum TBEV anti-
body titers in dogs under suspicion for TBE, the risk of 
over diagnosing TBE is imminent.
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Table 1 Information on signalment, TBEV antibody titers in CSF and serum, and results of CSF analyzis of all dogs (n  =  89) included in 
the study
Data are presented as median and IQR
CSF cerebrospinal fluid; IQR interquartile range; TBEV tick-borne encephalitis virus; ab antibody
Variable Group A Group B Group C
Total number of dogs 89 20 36 33
Sex
 Female 12 (60.0%) 15 (41.7%) 8 (24.2%)
 Neutered female 2 (10.0%) 2 (5.6%) 4 (12.1%)
 Male 3 (15.0%) 17 (47.2%) 14 (42.4%)
 Neutered male 3 (15.0%) 2 (5.6%) 7 (21.2%)
Median age (years) 4.9 IQR 2.0–5.5 2.0 IQR 1.0–7.3 10.0 IQR 7.6–12.4
Median body weight (kg) 17.0 IQR 6.0–27.0 11.0 IQR 7.6–21.4 26.0 IQR 9.6–30.8
Median TBEV ab (U/mL) CSF 26.8 IQR 20.2–34.8 18.8 IQR 15.3–27.1 22.4 IQR 16.1–33.4
 Range TBEV ab (U/mL) CSF 2.7–194.3 13.6–115.6 9.6–81.3
Number of dogs with CSF ab  >  126 U/mL 3 (15.0%) 0 0
Median TBEV ab (U/mL) serum 26.3 IQR 20.1–129.3 22.3 IQR 16.2–38.5 40.9 IQR 24.6–76.5
 Range TBEV ab (U/mL) serum 20.1–930.3 16.2–430.7 15.1–171.1
Number of dogs with serum ab > 126 U/mL 5 (25.0%) 4 (11.1%) 2 (6.1%)
Number of dogs with CSF pleocytosis 13 (65.0%) 11 (30.6%) Not analysed
Median number of leukocytes in CSF 16.0 IQR 2.5–40.5 2.5 IQR 0.0–7.5 Not analysed
Median protein (g/L) in CSF 0.32 IQR 0.18–0.86 0.22 IQR 0.13–0.43 Not analysed
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